BeiGene Seeks Historic Third Listing in Shanghai, Complementing US and HK
The 11-year-old money-losing biotech has filed for a listing on Shanghai’s STAR Market to raise more than $3 billion Key Takeaways: BeiGene will become the world's first stock to be…
